ERBB2
ENSG00000141736
Target class
Kinase
Chromosome
17
Approved drugs
16
Clinical candidates (approved and in development)
46
- Approved drugs
- 16
- Clinical candidates (approved and in development)
- 46
- Chemical probe available
- Yes
- Target name
- ERBB2
- Gene name
- Erb-b2 receptor tyrosine kinase 2
- Gene symbol
- ERBB2
- Previous gene symbols
- NGL
- Protein name
- Receptor tyrosine-protein kinase erbB-2 (EC 2.7.10.1) (Metastatic lymph node gene 19 protein) (MLN 19) (Proto-oncogene Neu) (Proto-oncogene c-ErbB-2) (Tyrosine kinase-type cell surface receptor HER2) (p185erbB2) (CD antigen CD340)
- NEU
- HER-2
- CD340
- HER2
- c-ERB2
- c-ERB-2
- MLN-19
- p185(erbB2)
- Gene biotype
- Protein coding
- Gene family
- CD molecules|Minor histocompatibility antigens|Erb-b2 receptor tyrosine kinases|MicroRNA protein coding host genes
- Target class
- Kinase
- Target type
- Human gene
- Tissues expressed in
- 54
- Protein localisation evidence grade
- Enhanced
- Highest tissue expression
- 130.13
- Tissue specificity (Gini)
- 0.484
- Tissue specificity (tau)
- 0.722
- KEGG gene identifiers
- hsa:2064
- Protein interaction confidence
- 0.834219
- Protein interaction partners
- 219
- R-HSA-1227986
- R-HSA-1250196
- R-HSA-1251932
- R-HSA-1257604
- R-HSA-1306955
- R-HSA-1358803
- R-HSA-1963640
- R-HSA-1963642
- R-HSA-2219530
- R-HSA-416572
- R-HSA-5673001
- R-HSA-6785631
- R-HSA-6811558
- R-HSA-8847993
- R-HSA-8863795
- R-HSA-8866910
- R-HSA-9634285
- R-HSA-9652282
- R-HSA-9664565
- R-HSA-9665233
- R-HSA-9665244
- R-HSA-9665245
- R-HSA-9665246
- R-HSA-9665247
- R-HSA-9665249
And 8 more, listed on the interactive page.
- End position
- 39730426
- Start position
- 39687914
- Chromosome
- 17
- Strand
- Forward
- Cell membrane
- Single-pass type I membrane protein . Cell projection, ruffle membrane
- Single-pass type I membrane protein . Note=Internalized from the cell membrane in response to EGF stimulation. .
- SUBCELLULAR LOCATION: [Isoform 1]: Cell membrane
- Single-pass type I membrane protein . Early endosome . Cytoplasm, perinuclear region. Nucleus. Note=Translocation to the nucleus requires endocytosis, probably endosomal sorting and is mediated by importin beta-1/KPNB1. Also detected in VPS35-positive endosome-to-TGN retrograde vesicles (PubMed:31138794). .
- SUBCELLULAR LOCATION: [Isoform 2]: Cytoplasm. Nucleus.
- SUBCELLULAR LOCATION: [Isoform 3]: Cytoplasm. Nucleus.
- Cytosol
- Nucleoplasm
- Plasma membrane
- PubMed 32381043
- PubMed 34380438
- PubMed 31138794
- PubMed 33497358
- Tissue specificity (tau)
- 0.722458
- Expression inequality (Gini)
- 0.484421
Expression in transcripts per million
- Nerve - Tibial
- 130.13
- Skin - Sun Exposed (Lower leg)
- 118.26
- Esophagus - Mucosa
- 113.1
- Skin - Not Sun Exposed (Suprapubic)
- 110.94
- Thyroid
- 99.31
Expression in transcripts per million
- Nerve - Tibial130.13
- Skin - Sun Exposed (Lower leg)118.26
- Esophagus - Mucosa113.1
- Skin - Not Sun Exposed (Suprapubic)110.94
- Thyroid99.31
- Artery - Aorta84.45
- Minor Salivary Gland83.83
- Prostate83.77
- Vagina78.81
- Artery - Tibial65.22
- Kidney - Medulla64.82
- Cervix - Ectocervix60.61
- Artery - Coronary55.06
- Kidney - Cortex53.57
- Colon - Transverse51.18
- Cervix - Endocervix50.03
- Uterus48.03
- Fallopian Tube47.86
- Lung47.78
- Small Intestine - Terminal Ileum44.18
- Ovary38.72
- Heart - Atrial Appendage38.38
- Breast - Mammary Tissue36.91
- Bladder36.5
- Cells - Cultured fibroblasts36.22
And 29 more, listed on the interactive page.
- GO:0006468
- GO:0007165
- GO:0007166
- GO:0007167
- GO:0007169
- GO:0008283
- GO:0018108
- GO:0030307
- GO:0032886
- GO:0035556
- GO:0038134
- GO:0042060
- GO:0043406
- GO:0043491
- GO:0045727
- GO:0045785
- GO:0045943
- GO:0050679
- GO:0070372
- GO:0071363
- GO:0071364
- GO:0090314
- GO:0005634
- GO:0005654
- GO:0005769
- GO:0005829
- GO:0005886
- GO:0010008
- GO:0016323
- GO:0038143
- GO:0043235
- GO:0001042
- GO:0004713
- GO:0004714
- GO:0004888
- GO:0005102
- GO:0005515
- GO:0019838
- GO:0030971
- GO:0042802
- GO:0043125
- GO:0046982
heart disease
Studies
- preclinical: Important for the heart and vasculature based on findings in genetically modified or kinase-inhibitor-treated mice. Role of kinase in heart/vasculature: Cardiomyocyte survival and homeostasis; maintenance of left ventricular function
Biological samples
- cardiovascular system
PubMed 21283106
Related records
Trials (2,542)
- -02341066 and PF-00299804 for Advanced Non-Small Cell Lung Cancer
- "Neo-Adjuvant Treatment With Palbociclib: Effect on Ki67 and Apoptosis Before, During and After Treatment "
- "Phase II Study of PET Guided Neoadjuvant Chemotherapy (NAC) and Oncotype Guided Hormonal Therapy of Breast Cancer"
- 12 weekS Adjuvant dOcetaxel Plus trastuzumaB in Patients With Small, Node-negative, HER2-positive Breast cancER (SOBER)
- 1303GCC: Trastuzmab & Pertuzumab With Hormonal Therapy or Chemotherapy in Women Aged 60 and Over.
- 18F-FDG Uptake Heterogeneity Predicts Pyrotinib Response
- 4-1BB Agonist Monoclonal Antibody PF-05082566 With Trastuzumab Emtansine or Trastuzumab in Treating Patients With Advanced HER2-Positive Breast Cancer
- 6 Weeks Treatment of Locally Advanced Breast Cancer With BIBW 2992 (Afatinib) or Lapatinib or Trastuzumab
- 64-Cu Labeled Brain PET/MRI for MM-302 in Advanced HER2+ Cancers With Brain Mets
- 89Zr-Trastuzumab PET/CT in Subjects With Previously Treated HER2-Positive Solid Tumors Scheduled to Receive Treatment With MT-5111
- 89ZrTrastuzumab Breast Imaging With Positron Emission Tomography
- A 1-year Multi-center, Prospective, Cohort Study in Patients With Chronic Obstructive Pulmonary Disease Treated With Long-acting Bronchodilator
- A Bioavailability Study of GS1-144 Tablets in Healthy Postmenopausal Women
- A Bioavailability Study of Two Different PEG-rhGH Preparations.
- A Bioequivalence Study of Two Different PEG-rhGH Preparations
- A Bioequivalence Study of Two Different PEG-rhGH Preparations.
- A Bioequivalence Study of Two Different Processes of PEG-rhGH Preparations
- A Biomarker-implemented Clinical Study Evaluating Mutations in MET and TP53 in a Population of Treatment-refractory Squamous Cell Carcinoma
- A Clinica Study of Pyrotinib in Patients of Advanced Non-Small Cell Lung Cancer With HER2 Mutation
- A Clinical Study Comparing Anti-HER2 Therapy Combined With Chemotherapy to Chemotherapy Alone as Adjuvant Therapy Following Surgery for Stage IB-II Gastric Cancer With High HER2 Expression.
Drugs (50)
- AC-480 Receptor protein-tyrosine kinase erbB-2 inhibitor
- AEE-788 Receptor protein-tyrosine kinase erbB-2 inhibitor
- Afatinib Receptor protein-tyrosine kinase erbB-2 inhibitor
- Afatinib dimaleate Receptor protein-tyrosine kinase erbB-2 inhibitor
- Allitinib Receptor protein-tyrosine kinase erbB-2 inhibitor
- Anvatabart opadotin Receptor protein-tyrosine kinase erbB-2 binding agent
- AV-412 Receptor protein-tyrosine kinase erbB-2 inhibitor
- AV-412 FREE BASE Receptor protein-tyrosine kinase erbB-2 inhibitor
- BMS-690514 Receptor protein-tyrosine kinase erbB-2 inhibitor
- Canertinib Receptor protein-tyrosine kinase erbB-2 inhibitor
- Canertinib dihydrochloride Receptor protein-tyrosine kinase erbB-2 inhibitor
- CP-724714 Receptor protein-tyrosine kinase erbB-2 inhibitor
- CUDC-101 Receptor protein-tyrosine kinase erbB-2 inhibitor
- Dacomitinib Receptor protein-tyrosine kinase erbB-2 inhibitor
- Dacomitinib anhydrous Receptor protein-tyrosine kinase erbB-2 inhibitor
- Disitamab vedotin Receptor tyrosine-protein kinase erbB-2 binding agent
- Ertumaxomab Receptor protein-tyrosine kinase erbB-2 cross-linking agent
- Gancotamab Receptor protein-tyrosine kinase erbB-2 binding agent
- Hemay-022 Receptor protein-tyrosine kinase erbB-2 inhibitor
- JNJ-26483327 Receptor protein-tyrosine kinase erbB-2 inhibitor